Get the Stockscreener App
2.18
0.93%
0.02
Pre-market:
2.20
0.02
+0.92%
Ensysce Biosciences Inc stock is traded at $2.18, with a volume of 35,238.
It is up +0.93% in the last 24 hours and down -8.02% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$2.16
Open:
$2.15
24h Volume:
35,238
Relative Volume:
0.10
Market Cap:
$6.47M
Revenue:
-
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.7243
EPS:
-3.01
Net Cash Flow:
$-9.78M
1W Performance:
-2.24%
1M Performance:
-8.02%
6M Performance:
-27.81%
1Y Performance:
-74.77%
1-Day Range:
$2.13
$2.18
1-Week Range:
$2.0401
$2.255
52-Week Range:
$1.62
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
2.18 | 6.41M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ensysce Biosciences Inc Stock (ENSC) Latest News
How high can Ensysce Biosciences Inc. stock go2025 Geopolitical Influence & Reliable Breakout Stock Forecasts - newser.com
What the charts say about Ensysce Biosciences Inc. todayMarket Trend Summary & Consistent Profit Trade Alerts - newser.com
Will Ensysce Biosciences Inc. stock gain from strong economy2025 AllTime Highs & Low Drawdown Investment Strategies - newser.com
Will Ensysce Biosciences Inc. stock remain a Wall Street favoriteJuly 2025 Setups & Accurate Trade Setup Notifications - newser.com
Momentum divergence signals in Ensysce Biosciences Inc. chart2025 Investor Takeaways & Real-Time Chart Breakout Alerts - newser.com
Why retail investors pile into Ensysce Biosciences Inc. stockPortfolio Value Report & Low Drawdown Investment Strategies - newser.com
How Ensysce Biosciences Inc. stock compares to industry benchmarksTrade Analysis Report & Weekly Momentum Picks - newser.com
Key metrics from Ensysce Biosciences Inc.’s quarterly dataWeekly Loss Report & High Conviction Trade Alerts - newser.com
Why analysts remain bullish on Ensysce Biosciences Inc. stockBull Run & Fast Exit/Entry Strategy Plans - newser.com
Published on: 2025-10-31 05:19:24 - newser.com
What makes Ensysce Biosciences Inc. stock attractive to growth funds2025 Dividend Review & Stepwise Trade Execution Plans - newser.com
Published on: 2025-10-31 03:53:54 - newser.com
How currency fluctuations impact Ensysce Biosciences Inc. stockPortfolio Update Summary & Weekly High Return Forecasts - newser.com
Using flow based indicators on Ensysce Biosciences Inc.Day Trade & Reliable Breakout Stock Forecasts - newser.com
Price to sales ratio of Ensysce Biosciences, Inc. – BOATS:ENSC - TradingView
Ensysce Biosciences’ Innovative Approach to Safer Opioid Use: A Clinical Study Update - TipRanks
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):